NPS

Displaying 1 - 20 of 226

Publication thumbnail

EMCDDA technical report on the new psychoactive substance N,Ndiethyl- 2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene)

The purpose of this technical report is to provide an analysis of the available information on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (commonly known as isotonitazene), an opioid analgesic that has recently emerged on the drug market in Europe, to...

Events

Meeting on the risk assessment of the new psychoactive substance isotonitazene

The extended Scientific Committee of the EMCDDA meets on 26 May 2020 to examine the risk assessment by the EMCDDA on isotonitazene.

EMCDDA initial report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene)

Isotonitazene is a synthetic opioid analgesic monitored by the EMCDDA as a new psychoactive substance through the European Union Early Warning System since 2019. Based on potential public health risks, an initial report has been prepared and submitted to the Commission and the Member States, in...

Publication cover_EWS guidelines

EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances

These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) with respect to information...

Infographic showing overview of NPS in Europe

Infographic: new psychoactive substances (NPS) overview — substances reported to the EU Early Warning System since 1997

This conceptual graphic from the EU Drug Markets Report 2019 presents an overview of new psychoactive substances (NPS) reported to the EU Early Warning System since 1997.

Document library

Document library

New psychoactive substances: challenges for drug surveillance, control, and public health responses

2nd International Scientific School "Novel Psychoactive substances: focus on Novel Synthetic Opioids"

This International Scientific School constitutes a unique opportunity for undergraduate or post-graduate students, PhD students, and post-doctoral scientists at an early stage in their career to gain...

12th Annual Meeting of the Expert Group on the Prevention of Drug Precursors' Diversion

The 12th Annual Meeting of the Expert Group on the Prevention of Drug Precursors' Diversion, organised by the Pompidou Group, takes place in Lisbon from 1-3 October. The EMCDDA will be present during...

2019 Annual meeting European Network of Forensic Science Institutes (ENFSI) – Drug working goup

The purpose of ENFSI as a network of experts is to share knowledge, exchange experiences and come to mutual agreements in the field of forensic science. The Drugs Working Group (DWG) supports the...

Conference promotional banner showing windmill in background

VI International Conference on Novel Psychoactive Substances (NPS)

The Sixth international conference on novel psychoactive substances will take place from 8–9 April 2019 in Maastricht. The conference will cover a wide range of topics, including: sharing evidence-...

Events

National Reitox academy on ‘Health effects of New Psychoactive Substances’

The National Reitox Academy is organised by the EMCDDA and the Ministry of Health of Serbia. The main objectives of this seminar are to clarify what a New Psychoactive Substance (NPS) is, its...

New legislation, bringing faster response to new drugs, applies from today

Europe’s ability to rapidly respond to public health and social threats caused by new psychoactive substances (NPS/‘new drugs’) will be significantly strengthened, thanks to new legislation applying from today (1). The legislation — applicable across Europe from 23 November 2018 — strengthens the...

Overview of EU early warning system (EWS) regulation

Infographic: New legislative system to tackle new psychoactive substances

The legislation — applicable across Europe from 23 November 2018 — strengthens the EU Early Warning System (EU EWS) and risk assessment procedures on NPS and shortens control processes.

screenshot

EU Early Warning System on NPS

This page describes the work and main outputs of the EU Early Warning System on new psychoactive substances. It includes a description of how the system work, an historical timeline of legislation and substances investigated, and NPS drug profiles.

Events

Novel Psychoactive Substances (NPS) Symposium

The Center for Forensic Science Research & Education is hosting a first of its kind, 2-day symposium on the status of the Novel Psychoactive Substances (NPS) crisis in the United States. Two...

Document library

Document library

Council Decision on cyclopropylfentanyl and methoxyacetylfentanyl

This is the implementation decision of the Council of the EU, based on a proposal from the European Commission, was adopted in the final stage of the three-step legal procedure designed to respond to...

eu flag

Two new synthetic opioids to be placed under control across the EU

Today, the European Union has decided to subject two new synthetic opioids to control measures across the 28 Member States. The implementing decision of the Council of the EU (1), based on a proposal from the European Commission, was adopted in the final stage of the three-step legal procedure...

Report on the risk assessment of 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. On the basis of the Risk Assessment Report — and on the...

Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. On the basis of the Risk Assessment Report — and on...

EMCDDA–Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA

This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2017...

1
2
3
4
5
6
7
8
9
…
next ›

.

Loading